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qPCRThe use of the anti-inﬂammatory drug indomethacin (INDO) in preterm infants has been associated with an
increased risk of developing enteropathies. In this study, we have investigated the direct impact of INDO on
the human mid-gestation intestinal transcriptome using serum-free organ culture. After determining the
optimal dose of 1 μM of INDO (90% inhibition of intestinal prostaglandin E2 production and range of circulat-
ing levels in treated preterm babies), global gene expression proﬁles were determined using Illumina bead
chip microarrays in both small and large intestines after 48 h of INDO treatment. Using Ingenuity Pathway
Analysis software, we identiﬁed critical metabolic pathways that were signiﬁcantly altered by INDO in both
intestinal segments including inﬂammation and also glycolysis, oxidative phosphorylation and free radical
scavenging/oxidoreductase activity, which were conﬁrmed by qPCR at the level of individual genes. Taken
together, these data revealed that INDO directly exerts multiple detrimental effects on the immature
human intestine.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) such as indometha-
cin (INDO) have beenwidely used in the neonatal period for prevention
and closure of persistent patent ductus arteriosus (PDA) [1–3] aswell as
a tocolytic agent [4]. PDA remains one of the most frequent complica-
tions in the clinical management of preterm infants. A persistent PDA
in preterm neonates causes pulmonary congestion [5] and decreased
blood ﬂow to vital organs [6] leading to various additional complica-
tions. PDA has an incidence of 40–80% in premature infants with low
birthweight [1,7] but can be treated effectively with NSAID administra-
tion leading to permanent ductal closure in 60–80% of infants [2,3].
INDO has also been efﬁciently used since the 1970s to delay delivery
in cases of preterm labor [4]. However, the use of NSAIDs in the neonate
is associated with a broad spectrum of life-threatening adverse effects
on various systems, most notably on the gastrointestinal tract [4,8]
where INDO treatment was associated with an alteration in bloodthacin; IPA, Ingenuity Pathway
nonsteroidal anti-inﬂammatory
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NC-ND license.ﬂow and increased risk of developing necrotizing enterocolitis (NEC)
with intestinal perforation [9–13].
In the adult, NSAIDs are known to cause severe gastrointestinal
injuries ranging from frequent asymptomatic inﬂammation, erosions,
ulcers and altered mucosal permeability [14–16]. These side effects of
NSAIDs are a result of their ability to inhibit the COX enzymes, COX1
and COX2, which are involved in the conversion of arachidonic acid to
prostaglandin. While the decrease of prostaglandin synthesis is wide-
ly acknowledged as the basis of the gastrointestinal toxicity caused by
these drugs [14–16], the inhibition of COX alone may not completely
explain all the gastrointestinal damage caused by these drugs. For
instance, it has been demonstrated that disruption of the COX genes
alone did not provoke gastrointestinal injury in rodents in the absence
of injurious stimuli [17] suggesting that complementary mechanisms
may be involved in causing digestive mucosal damage [18,19]. Addi-
tional studies on experimental animalmodels suggest that the develop-
ment of NSAID-mediated enteropathy requires uncoupling of intestinal
mitochondrial oxidative phosphorylation and/or inhibition of the respi-
ratory chain [20]. Oxidative stress is another putative mechanism pro-
posed to be associated with the adverse effects caused by NSAIDs.
Indeed, previous studies have reported that INDO can induce apoptosis
in intestinal epithelial cell lines [21] by generating the production of
reactive oxygen free radicals and could be one of the mechanisms by
which INDO damages intestinal mucosa [22]. In a recent study, INDO
was shown to favor bacterial translocation across the epithelial
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ther emphasizing INDO-induced barrier dysfunction. Nitric oxide (NO)
could also be involved in the side effects of NSAIDs. NO is a scavenger
of free radicals [24] playing an important role in maintaining mucosal
integrity [25]. Evidence suggests that NSAIDs may induce gastrointesti-
nal injuries by interfering with both mucosal synthesis and availability
of NO [26]. Taken together, data generated in experimental animal
models, although still fragmentary, suggest that NSAIDs may affect
intestinal mucosa integrity via both COX-dependent and independent
mechanisms.
Despite increasing scientiﬁc progress in establishing the pathways
involved in NSAID-induced damage, understanding the pathogenesis
of gastrointestinal injury byNSAIDs in neonates relies on a limited num-
ber of studies carried out in animal models. In the present study, we
exploited our experience inmaintainingmid-gestation human intestine
in serum-free organ culture [27,28] with global gene expression analy-
sis [29–31] to investigate the speciﬁc intestinal effects of INDO on the
overall physiology of both small and large intestines at mid-gestation.
Our results established that INDO negatively impacts several crucial
metabolic and physiological pathways, such as glycolysis, oxidative
phosphorylation, and free radical scavenging in the immature intestinal
mucosa and begins to deﬁne the molecular elements directly affected
in the mid-gestation intestine under deﬁned conditions by this anti-
inﬂammatory drug.
2. Results
2.1. Determination of INDO concentration for inhibition of intestinal
PGE2
We ﬁrst performed a dose–response curve analysis to determine the
appropriate working concentration of INDO to use in organ cultures of
mid-term intestinal tissue. In preterm infants, previous in vivo studies
showed that optimum PDA closure rates with intravenous INDO could
be achieved with plasma levels varying between 0.5 and 5 μM [32,33].
Levels of PGE2 were measured and assumed to reﬂect COX activity,
the target of INDO inhibition. As shown in Fig. 1, increasing concentra-
tions of INDO markedly decreased the production and release of PGE2
by both small and large intestinal segments compared to controls.
INDO signiﬁcantly inhibited PGE2 production by over 90% at concentra-
tions of 100 nM INDOormore, conﬁrming that intestinal organ cultures
were responsive to INDO. In the context that previous studies indicating
that INDOwas active on intestinal epithelial cell lines in ranges between
1 and 1000 μM [21,23], we therefore decided to perform our studiesFig. 1. Inhibition of PGE2 production by INDO in the human small intestine and colon at
mid-gestation. Changes in intestinal PGE2 levels after 48 h of culture in the presence of in-
creasing concentrations of INDO. Data are expressed as percentage of inhibition of PGE2
compared to corresponding untreated control segments. Values shown are the mean of
3 independent biological samples. *pb0.05 and **pb0.001 vs untreated control segments.with 1 μM INDOwhich is also representative of theminimumnecessary
dose required to close the PDA andwhich successfully inhibits its target
in both segments in organ culture.
2.2. Global gene expression analysis of the effect of INDO on the mid-
gestation human small and large intestines
To investigate the modulatory inﬂuence of INDO on gene expres-
sion proﬁles in the mid-gestation intestine, matched control and
INDO-treated (1 μM) explants prepared from 4 ileums and 4 colons
were cultured in serum-free medium for 48 h. Gene expression pro-
ﬁles were then determined using Illumina whole genome expression
beadchip microarrays providing coverage of more than 47,000 tran-
scripts for each of the 16 samples. Statistical analyses revealed that
295 and 138 genes were signiﬁcantly and differentially expressed
by INDO in the ileum and the colon, respectively, in comparison to
controls (Supplementary Tables 1 and 2 for gene lists). We noted
that only 35 of these genes were common between the two segments.
Of the 295 differentially expressed genes in the ileum, 153 were
up-regulated and 142 were down-regulated, while only 41 were
up-regulated and 97 were-down-regulated of the 138 found in the
colon (Fig. 2). The original data have been deposited in the National
Center for Biotechnology Information's Gene Expression Omnibus
and are accessible through GEO Series accession number GSE38406.
2.3. Common pathways modulated by INDO in the mid-gestation human
small and large intestines
All signiﬁcantly and differentially expressed genes in response to
INDO treatment in the ileum and colon were independently subjected
to IPA software which groups genes by molecular and cellular func-
tions. IPA analysis identiﬁed several enriched functional networks
modulated by INDO in the immature intestine. Table 1 shows three
of the most signiﬁcant and representative networks for each segment
(see Supplementary Tables 3 and 4 for complete network and gene
lists). It is noteworthy that several network biological functions iden-
tiﬁed in both segments were related to inﬂammatory functions such
as “cellular movement”, “cell death”, “DNA replication and cellular
growth”, “inﬂammatory response”, and “gastrointestinal diseases”,
consistent with the expected anti-inﬂammatory effect of INDO in
the immature intestine.Fig. 2. Genesmodulated by INDO in thehuman small intestine and colon atmid-gestation.
A) Intersection between up-regulated genes in the small intestine (ileum) and colon.
Numbers represent differentially up-regulated genes by INDO in each tissue. B) Intersec-
tion between down-regulated genes in the ileum and colon. Numbers represent differen-
tially down-regulated genes by INDO in each tissue.
Table 1
Biological functions modulated by INDO exposure in the mid-gestation human intestine.
Associated
networks
Molecules in network Score Focus Top functions
Small intestine
#1 ACTG2, ADM, ATP1B1, BCR, CD24, CDC42SE2, DAB2, EIF4B, ERK1/2,
FLNC, FSH, GPA33, HSPB1, ID1, IgG, Interferon alpha, ISG20, Jnk,
KDM3A, KLF4, LGMN, LIMS1, LIPA, MT1H, MT1X, NOS2, OGG1, PDGF
BB, PDGFRA, PFKP, PGK1, Pkc(s), TCR, TPM2, VEGFB
36 26 Cellular movement, DNA replication, Recombination, and repair,
cancer
#2 CASP5, CCL7, CDKN1A, CEACAM1 (includes others), CSF2, CTNNB1,
CTSB, CXCL5, DDX17, EPCAM, GHR, GNS, GPX2, HAS1, HLA-DQ, IL37,
IL1B, IL1RAP, ITGAX, JAK2, KLF4, KLK2, lymphotoxin-alpha1-beta2,
PSAP, RBM3, RHOU, SERPINA3, STMN2, TACR1, TFEB, TIFA, TNFAIP6,
TREM1, TSC22D1, TSPAN8
17 16 Carbohydrate Metabolism, inﬂammatory response, cell-to-cell
signaling and interaction
#3 CCL20, CD36, CD274, COL1A2, EPAS1, EVL, FAM162A, FCER2, GFI1,
GLRX, GPX4, HCK, IL2, IL13, IL22, IL33, IL2RG, LAMA4, MAP3K14,
MAPK1, NOS2, NOS3, PDCD1, PLD1, PSMD4, PSME2, RELA, RPL4, SPN,
TMEM45A, TNFSF12, TPT1 (includes EG:100043703), TSLP, UGP2,
ZEB2
13 13 Inﬂammatory Response, cellular movement, immune cell
trafﬁcking
Colon
#1 CASP1, CCL3, CCL20, CCNB2, CXCL1, CXCL2, CXCL5, DEFB4A/DEFB4B,
Focal adhesion kinase, GPX4, HSPE1, IFN Beta, IL6, Immunoglobulin,
INSIG1, Interferon alpha, LCN2, LDL, LIPG, NAMPT, NFkB (complex),
NFKBIZ, Nr1h, NR4A2, P38 MAPK, PDGF BB, PI3K (complex), PIGR,
RARRES3, SLC2A3, SLC5A1, SST, TFPI2, TNFRSF11B, UBD
43 25 Inﬂammatory response, cellular movement, hematological
system development and function
#2 ADM, Akt, APP, ASAH1, ATP1B1, BNIP3, CCL19, CDC25A, CDCA5,
CHEK1, COL18A1, EFNA1, ERK, ERK1/2, FSH, HIST1H4A (includes
others), HSPB1, IgG, IL36A, IL36G, Jnk, LGALS1, Lh, MAPK8IP1, PAWR,
PGK1, Pkc(s), PPIA, PTP4A3, RNA polymerase II, S100A9, SLC2A3, TCR,
TNFRSF21, tyrosine kinase
25 17 Cell death, DNA replication, recombination, and repair, cancer
#3 ACSS2, AFP, ALB, ANAPC2, ATF3, BUB1B, C4BPA, C5orf13, CDC20,
CDC27, DSTN, FURIN, FZR1, HMGCS2, HMOX1, HNF1A, IGFBP1
(includes EG:16006), MAPT, miR-20a/miR-106b/miR-17-5p (includes
others), Nuclear factor 1, PPARA, RAC1, RASSF1, RB1, RUNX1, SCD,
SERPINA1, SERPINA3, SPHK1, TFRC, TGFB2, TGFB1 (includes EG:21803), TGFBI,
TJP1 (includes EG:21872), UHRF1
14 11 Cellular growth and proliferation, cancer, gastrointestinal disease
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a comparative analysis of the cellular, molecular, physiological and
metabolic functions consisting of clusters of several individual genes
was performed and classiﬁed according to statistical signiﬁcance in
the variation of the expression of genes in each category. Supplemen-
tary Tables 5 and 6 list 79 and 81 categories for the small and large
intestines, respectively, which were sorted according to their statisti-
cal signiﬁcance as the negative logarithm of p-values calculated by
IPA. Plotting the negative logarithm of p-values calculated by IPA for
each of the functional categories found in the ileum against the neg-
ative logarithm of p-values of the corresponding categories found in
the colon allows visualization of functions that are most relevant to
each segment. As summarized in Fig. 3, more than 85% (71 out of 81)
of the signiﬁcant categories were altered in both ileum and colon
while the remaining 15% (10 out of 81) were speciﬁc to either the
ileumor the colon. Among the shared pathwayswere various biological
processes known to be inﬂuenced by INDO (identiﬁed by blue markers
in Fig. 3) such as “cellular growth and proliferation”, “cell death”, “drug
metabolism”, “gastrointestinal diseases”, “inﬂammatory response”, and
“acute phase response signaling”.
We also observed that several important metabolic functions less
commonly reported to be associatedwith INDO treatment were also sig-
niﬁcantly represented in both intestinal segments namely “glycolysis/
gluconeogenesis” and “free radical scavenging” (identiﬁed by red
markers in Fig. 3) establishing that INDOalsomodulates these physiolog-
ical processes in the immature gut. Moreover, we also identiﬁed speciﬁc
metabolic pathways that were found to be modulated in unique intesti-
nal segments such as “pentose phosphate pathway” and “production of
nitric oxide and reactive oxygen species in macrophages” categories,
which were exclusively modulated in the small intestine, while “mito-
chondrial dysfunction” and “glutathione metabolism” were found to be
affected only in the colon (indentiﬁed by green markers in Fig. 3),suggesting that INDO could have differential non-inﬂammatory effects
along the immature intestine.
2.4. Validation of microarray results by quantitative PCR
To further investigate the ﬁnding that “glycolytic metabolism”, “free
radical scavenging activity” and/or “oxidoreductase activity” and
“inﬂammatory response” appeared to be highly modulated by INDO in
the gut according to the microarray data, speciﬁc genes were selected
from these categories and their expression was measured by quantita-
tive PCR (qPCR). As shown in Fig. 4A, a signiﬁcant down-regulation of
genes involved in glycolysis in both intestinal segments was observed
for LDHA and in at least one segment for ENO1, ALDOA and PGK1
(colon) and HK2 (ileum). For oxidative phosphorylation (Fig. 4B),
screening for two genes involved in this category revealed a signiﬁcant
down regulation of NDUFA9 in both ileum and colon and the reduction
of ATP5G1 in the colon. By determining the expression levels of genes
involved in oxidoreductase activity (Fig. 4C), we observed that
CYP3A4 was signiﬁcantly up-regulated by INDO in both intestinal seg-
ments, while DUOX2 was signiﬁcantly down-regulated only in the
small intestine. NOS2 was strongly down-regulated in the ileum while
SOD2 expressionwas exclusively repressed in the colon. Finally, expres-
sion of genes of the inﬂammatory response family (Fig. 4D) was also
inﬂuenced by INDO as conﬁrmed by the increased expression of the
chemokine CXCL14 and repression of TFF1 in both segments and the
decreased expression of CXCL5 in the ileum.
3. Discussion
Because of their effectiveness, NSAIDs such as INDO have been
widely used for nearly 4 decades as treatment for PDA [1–3] or as a
tocolytic agent [4]. However, there is still an open debate concerning
Fig. 3. Cellular, molecular and physiological functions modulated by INDO in the human small intestine and colon at mid-gestation. The negative logarithm of p-values (Fisher's test),
calculated by IPA, for each of the functional categories affected by INDO in the small intestine was plotted against the negative logarithm of p-values of the corresponding categories
in the colon. Using Illumina whole genome expression beadchip microarrays, IPA analysis revealed that both intestinal segments share 85% of the 81 molecular and cellular functions,
but some functional categories were found to be exclusively represented in each tissue (8/79 and 8/81 for the ileum and colon, respectively). Blue and red markers indicate
injury-related functions common to ileum and colon while green markers identiﬁed injury-related functions exclusive to the ileum or colon. Dotted lines denote the p=0.05 [−Log
(0.05)=1.3] thresholds.
Fig. 4. Differential effects of INDO on markers of the glycolysis, oxidative phosphorylation, oxidoreductase activity and inﬂammatory response networks in the human small intes-
tine and colon at mid-gestation. Real-time quantitative PCR analysis of transcript levels of A) glycolytic enzymes (ALDOA, ENO1, HK2, LDHA, and PGK1), B) oxidative phosphory-
lation (ATP5G1 and NDUFA9), C) oxidoreductase activity (CYP3A4, DUOX2, NOS2 and SOD2) and D) inﬂammatory response (CXCL14, CXCL5 and TFF1) after 48 h of culture in the
presence of INDO (1 μM) in the mid-gestation human ileum and colon. Samples were normalized to RPS3A and data are expressed as ratios of INDO treated over untreated seg-
ments, expressed on a Log2 scale. Values shown are the mean of three to four independent biological samples. *pb0.05 vs corresponding untreated control segments.
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175N. Perron et al. / Genomics 101 (2013) 171–177the possible deleterious fetal and neonatal effects of INDO based on
multiple studies that have shown increased neonatal complications
with it use, such as necrotizing enterocolitis [9–13]. Until now, the
pathogenesis of intestinal damage induced by NSAIDs has been large-
ly studied in animal models and intestinal cell lines and the precise
molecular and cellular mechanisms of how INDO could injure the im-
mature human intestine remained unknown. In the present study,
using serum-free organ culture that allows the direct testing of bio-
logical effectors on the intestinal mucosa [27,28] andmicroarray anal-
ysis combined with the use of IPA and qPCR [29,31] to screen and
validate the repertoire of modulated gene expressions, we were
able to determine, for the ﬁrst time, the speciﬁc intestinal effects of
INDO on the overall physiology of the human intestine at mid-
gestation.
The gene expression proﬁles identiﬁed revealed that a large
proportion of statistically signiﬁcant cell, molecular, physiological
and metabolic functions is modulated by INDO in the mid-gestation
intestine. As expected for an NSAID effect on the intestinal mucosa
[14–16], a number of these signiﬁcantly modulated functions were
inﬂammation-related such as “inﬂammatory diseases”, “inﬂammato-
ry response”, “acute phase response” and “immune cell trafﬁcking”.
Interestingly, contrary to the anti-inﬂammatory effect of epidermal
growth factor [29], INDO exerted a similar modulatory effect on
inﬂammation-related functions in both small and large intestines. It
is noteworthy that the dose of 1 μM INDO used in these studies was
low compared to other studies performed on epithelial cell lines
[21]. The choice of this dose was based on reported intravenous levels
in preterm babies treated with INDO for PDA [32,33] and was further
conﬁrmed to be efﬁcient in inhibiting PGE2 production by 90% in the
mid-gestation intestine suggesting that the effects observed are phys-
iologically relevant to the in vivo situation.
Indeed, in vitro and experimental animal studies have suggested that
NSAIDs could exert additional effects on intestinal cells other than those
resulting directly from COX inhibition [17–19,23]. Herein, in agreement
with these observations, we have identiﬁed a series of metabolic-
related gene clusters that were found to be signiﬁcantly modulated in
thehumanmid-gestation intestine by INDO, even at a relatively low con-
centration. Some of these clusters were speciﬁc to the small intestine
such as the “pentose phosphate pathway” and “production of nitric
oxide and reactive oxygen species”, others were exclusively identiﬁed
in the colon such as “glutathione metabolism” and “mitochondrial dys-
function”while others were common to both segments such as “glycol-
ysis/gluconeogenesis”. These alterations affecting the regulation of the
glycolytic pathway and consequently oxidative phosphorylation and/or
electron transport are consistent with previous studies in rodents that
have demonstrated an inhibition of both glycolysis and oxidative phos-
phorylation induced by INDO [34–36], which in turn led to an increase
in intestinal permeability [37]. Furthermore, INDO was also shown to
favor bacterial translocation across enteric epithelia in a recent study
[23]. In this context, our results indicate that preterm infants exposed
to INDO could suffer from decreased mucosal protection thus being
less resistant to microbial invasion, an event that may be associated
with NEC.
To further investigate this possibility, we dissected these pathways
at the level of individual genes. First, the effect of INDO on genes related
to glycolysis/gluconeogenesis was observed. While an inﬂuence of
INDO on sugar metabolism had been suggested previously [37], the
direct effect of INDO on the speciﬁc down-regulation of glycolysis/
gluconeogenesis metabolism-related genes such as those encoding
ALDOA, ENO1, HK2, LDHA and PGK1 is shown herein for the ﬁrst time.
Another interesting ﬁnding was the marked effect of INDO on oxidore-
ductase activity in the immature gut at the level of individual genes
such as those encoding the antioxidant molecules CYP3A4, DUOX2,
NOS2 and SOD2. CYP3A4 is the most abundant CYP450 expressed in
the intestine and contributes to the metabolism of a large number of
drugs currently in clinical use [38,39]. Its signiﬁcant increase inresponse to exposure to INDO in the small and large intestines validated
the physiological and functional state of the intestinal mucosa in organ
culture, although immature. DUOX2, an enzyme involved in the pro-
duction of hydrogen peroxide in response to microbial invasion, has
been reported to play a role in innate immune defense in the gut
[40,41]. The NO system is one of the major effector systems implicated
in the inﬂammation process. The NOS2 transcript was found to be
down-regulated by INDO in the ileum. Although the role of iNOS-
induced NO in intestinal damage and healing is still controversial, it
can contribute to ulcer healing in INDO-treated rats [26,42]. Moreover,
NO donors have also been shown to reduce gastrointestinal mucosal
damage in animal models [43,44]. Finally, the expression of SOD2,
encoding a mitochondrial antioxidant enzyme, was speciﬁcally down-
regulated in the developing colon. Expression of this gene appears to
prevent the formation of reactive oxygen species to avoid mitochondri-
al dysfunction [45]. Interestingly, CXCL14, which has been shown to be
up-regulated by reactive oxygen species duringmitochondrial dysfunc-
tion in breast cancer [46], was found to be up-regulated in both intesti-
nal segments. Taken together, these ﬁndings suggest that the down-
regulation of the expression of genes encoding enzymes involved in
the response to oxidative stress is part of the mechanism by which
INDO raises the level of free radicals and mucosal damage.
Finally the down-regulation of CXCL5 in the small intestine and
TFF1 in both segments by INDO is noteworthy. Indeed, CXCL5 can
induce both new capillary growth and villus height during adaptation
after small bowel resection in mice [47] while TFF1 (trefoil factor
family 1) plays an important role in protecting the gastrointestinal
mucosa [48,49]. Both genes were previously found to be part of a
EGF-mediated anti-inﬂammatory response [29].
Taken together, this approach of combining organ culture of the
immature human intestine and transcriptomics allowed the demon-
stration that INDO modulates several different pathways in the imma-
ture human intestine other than those that are inﬂammation-related.
More speciﬁcally, we identiﬁed crucial physiological and metabolic
pathways such as glycolysis/gluconeogenesis, oxidative phosphoryla-
tion and oxidoreductase activities as the main targets of INDO in the
human mid-gestation intestine. By characterizing speciﬁc genes
involved in these pathways, we propose that INDO impairs glucose
metabolism and mitochondrial function resulting in ATP depletion
and an increased production of reactive oxygen species leading to a dis-
ruption of intestinal barrier function. These ﬁndings suggest a mecha-
nistic basis for better understanding the deleterious effects of INDO on
neonatal intestinal pathologies and emphasize the risk of using a
NSAIDs-based therapy on the immature gut.
4. Materials and methods
4.1. Tissues
Small intestinal (ileum) and large bowel (colon) tissues were
obtained from 13 fetuses ranging from 17 to 18 weeks gestation fol-
lowing legal or therapeutic pregnancy termination with informed
patient consent. No tissues were collected from cases associated with
known fetal abnormalities or intrauterine fetal demise. Studies were
approved by the Institutional Review Committee for the use of human
material from the “Centre Hospitalier Universitaire de Sherbrooke/
Faculté de Médecine et des Sciences de la Santé”.
4.2. Serum-free organ culture
Small and large intestinal tissues obtained from 13 fetuseswere pre-
pared as previously described [27–29]. Brieﬂy, each intestinal tissue
was cut into several 5×5-mm2 explants which were maintained in
organ culture dishes (Falcon Plastics, Los Angeles, CA) at an interface
of a 95% air-5% CO2 gas mixture and culture medium for up to 2 days
(37 °C). For each intestinal tissue, four culture dishes containing
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mental conditions (untreated and INDO-treated). INDO (Sigma-Aldrich,
St-Louis, MO) was added at a concentration of 10 nM to 300 μM for
prostaglandin E2 (PGE2) production studies, and at 1 μM for gene
expression studies. Explants were maintained in culture for 2 days
and media was changed daily.
4.3. Measure of intestinal prostaglandin E2 levels
The levels of PGE2 released in the culture medium were measured
after 48 h of culture in the presence or absence of various concentra-
tions of INDO (10 nM to 300 μM). Culture media were harvested and
the concentration of PGE2 was determined using a PGE2 enzyme-
immunoassay kit (Correlate-EIA, Assay Designs, Ann Arbor, MI) fol-
lowing the manufacturer's protocol.
4.4. RNA extraction
RNA was extracted with TRIzol (Invitrogen, Burlington, ON)
according to the manufacturer's protocol and stored at −80 °C. For
each sample, RNA was quantitated and quality was evaluated by
determining RNA integrity values (RIN values>7.0) as required for
microarray experiments.
4.5. Microarray screening and data analysis
Probes for microarray analysis were generated from RNA isolated
from 2 dishes of cultured explants for each of the 4 experimental con-
ditions (untreated vs INDO-treated; small vs large intestine) tested
on 4 sets of biological samples obtained from distinct fetuses for a
total of 16 samples (4 control ileums and 4 matched INDO-treated
ileums, 4 control colons and 4 matched INDO-treated colons). The
biological validity of these experimental conditions was recently
established [29]. The 16 samples were processed at the microarray
platform of the UHN Microarray Centre, University Health Network
(Toronto, ON). Two Illumina whole genome Human HT-12 v4 expres-
sion beadchips (12 samples per beadchip) were screened, analyzed
and quantile normalized via the UHN Microarray Centre (data are
accessible through GEO and are all MIAME compliant). A Mann–
Whitney test (pb0.05) was used to identify genes expressed differen-
tially (using TMEV 4.2 software).
4.6. IPA analysis
Functional analyses were performed using IPA 8.8 software
(Ingenuity Systems, www.ingenuity.com) as described previously
[29,31]. The reference lists containing differentially expressed genes
with gene identiﬁers and corresponding expression values wereTable 2
Primers used in this study.
Gene symbol Sense primer
ALDOA 5′-CGTTGTGTGCTGAAGATTGG-3′
ATP5G1 5′-ACAGCAACTTCCCACTCCAG-3′
CXCL5 5′-TGTTTACAGACCACGCAAGG-3′
CXCL14 5′-AAGCTGGAAATGAAGCCAAA-3′
CYP3A4 5′-CAAGACCCCTTTGTGGAAAA-3′
DUOX2 5′-CGGCAATCATCTATGGAGGT-3′
ENO1 5′-TTGGGAAAGCTGGCTACACT-3′
HK2 5′-GATTTCACCAAGCGTGGACT-3′
LDHA 5′-ACTGCAAACTCCAAGCTGGT-3′
NDUFA9 5′-CCGGAAGCCATTATCGTAAA-3′
NOS2 5′-CTCTATGTTTGCGGGGATGT-3′
PGK1 5′-CTGTGGGGGTATTTGAATGG-3′
RPS3A 5′-CCGGAAGAAGATGATGGAAA-3′
SOD2 5′-GGAAGCCATCAAACGTGACT-3′
TFF1 5′-CACCATGGAGAACAAGGTGA-3′uploaded into the IPA application. Each gene identiﬁer was mapped to
its corresponding gene object in the Ingenuity Knowledge Base. IPA
allows ﬁltering to consider only functions and interactions in protein
networks and/or pathways that are known for the deﬁned species and
tissue or cell line range. The stringent ﬁlter set for human and relaxed
ﬁlter for tissues and cell lines were used for the core analyses. Fisher's
exact test was used to calculate a p-value determining the probability
that each biological function assigned to that data set would be due to
chance alone.
4.7. Data validation by qPCR
RNA from the same sixteen samples used for microarray analyses
was used for qPCR conﬁrmation. All reactions were performed in dupli-
cate as previously described [29]. Brieﬂy, reactions were performed in
an Mx3000P real-time PCR system (Stratagene, Cedar Creek, TX)
starting with 10 min of Taq activation at 95 °C, followed by 40 cycles
of melting (95 °C, 30 s), primer annealing at the temperature appropri-
ate for each primer (55–60 °C, 45 s), and extension (72 °C, 45 s) ending
with amelting curve analysis to validate the speciﬁcity of the PCR prod-
ucts. Fluorescence data were acquired after each annealing step. Ampli-
ﬁcation efﬁciencies ranged from 91% to 105%. Brilliant II SYBR®Green
QRT-PCR Master Mix (Stratagene) was mixed with the appropriate
primers and high quality sterile water. The genes investigated were
aldolase A (ALDOA), ATP synthase, H+transporting, mitochondrial Fo
complex, subunit C1 (subunit 9) (ATP5G1), chemokine (C-X-C motif)
ligand 5 (CXCL5), chemokine (C-X-C motif) ligand 14 (CXCL14), cyto-
chrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4), dual oxi-
dase 2 (DUOX2), enolase 1 (ENO1), hexokinase 2 (HK2), lactate
dehydrogenase A (LDHA), NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex 9, 39 kDa (NDUFA9), nitric oxide synthase 2, inducible
(NOS2), phosphoglycerate kinase 1 (PGK1), ribosomal protein S3A
(RPS3A), superoxide dismutase 2 (SOD2), and trefoil factor 1 (TFF1).
Primers are listed in Table 2 andwere generated using the primer forma-
tion software Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi) with attention given to avoiding primer-dimer formation by
stringent use of the maximum 3′ self-complimentarity function of the
Primer3 program. Differences in gene expressionwere evaluated by com-
paring untreated vs INDO-treated samples for a given intestinal segment
using the equationR=(Etarget) ΔCttarget/(Ereference) ΔCtreference [50]. The ref-
erence gene used was the ribosomal protein S3A (RPS3A).
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2012.12.003.
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